Hormone receptor status-Negative (ER-/PR-) Posts on Medivizor
Navigation Menu

Hormone receptor status-Negative (ER-/PR-) Posts on Medivizor

Searching for patients with advanced triple-negative breast cancer to test a new combination treatment

Posted by on Aug 22, 2019 in Breast cancer | 0 comments

In a nutshell This phase 1b/2 trial will investigate the safety of cabozantinib (Cabometyx) with or without atezolizumab (Tecentriq) in patients with advanced solid tumors. The main outcomes will be maximum tolerated dose (MTD) and overall response rate (ORR). The details Advanced cancers have limited treatment options. Surgery may...

Read More

Searching patients with triple-negative breast cancer to trial a new treatment combination

Posted by on Jul 29, 2019 in Breast cancer | 0 comments

In a nutshell This phase 1b/2 trial will investigate the safety of treatment with rucaparib (Rubraca) in combination with other anti-cancer agents (ACAs) in patients with triple-negative breast cancer and other solid tumors. The main outcomes will be the number of treatment-related side effects and response to treatment. This trial is...

Read More

Looking patients with metastatic triple negative breast cancer to trial a radiation treatment

Posted by on Jun 29, 2019 in Breast cancer | 0 comments

In a nutshell This phase 2 trial will investigate the effectiveness of stereotactic body radiotherapy (SBRT) in patients with metastatic cancer. The main outcome will be progression-free survival (PFS; survival without the cancer getting worse).  This trial is recruiting in multiple locations in New York and New Jersey, US. The details...

Read More

Searching for patients with advanced triple negative breast cancer to test this new treatment option

Posted by on May 26, 2019 in Breast cancer | 0 comments

In a nutshell This phase 1/2 trial is examining the effectiveness and safety of KY1044 alone and in combination with atezolizumab (Tecentriq) for patients with advanced cancers who are not suitable for any other treatment or have failed all other treatment options. The main outcomes to be measured will be the occurrence and severity of side effects and...

Read More

Evaluating radiotherapy after surgery for patients with triple-negative breast cancer

Posted by on Apr 6, 2019 in Breast cancer | 0 comments

In a nutshell This study evaluated the impact of radiotherapy on the survival of patients with breast cancer who have undergone surgery. This study found that patients who had radiotherapy after surgery had higher survival than patients who had surgery only. Some background Triple-negative breast cancer (TNBC) is cancer that does not have...

Read More

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.

Posted by on Nov 11, 2018 in Breast cancer | 0 comments

In a nutshell This study wanted to see how well two medications worked in treating advanced triple negative breast cancer, atezolizumab (Tecentriq) and nab-paclitaxcel (Abraxane).  The study found that using these two medications together improved survival in these patients. Some background Triple-negative breast cancer (TNBC) is breast cancer...

Read More

ASCO 2017: Breast Cancer Research News

Posted by on Sep 28, 2017 in Breast cancer | 0 comments

Video information: Breast cancer experts gathered at the 2017 American Society of Clinical Oncology meeting to discuss developments in research and treatment. Patient Power founder, Andrew Schorr, was on-site in Chicago and interviewed Dr. Julie Gralow, Director of Breast Medical Oncology at the Seattle Cancer Care Alliance. Dr. Gralow shares...

Read More

Using paclitaxel, capecitabine and bevacizumab together to treat triple-negative metastatic breast cancer

Posted by on Sep 26, 2016 in Breast cancer | 0 comments

In a nutshell This study examined whether a combination of paclitaxel, capecitabine, and bevacizumab was safe and effective in treating triple-negative, locally-advanced metastatic breast cancer. The three drugs taken together were safe and highly effective in treating these patients. Some background In recent years, many new...

Read More

Is carboplatin + paclitaxel + bevacizumab safe and effective in triple negative breast cancer?

Posted by on Apr 16, 2015 in Breast cancer | 0 comments

In a nutshell This paper examined the safety and effectiveness of carboplatin (Paraplatin) and paclitaxel (Taxol) in combination with bevacizumab (Avastin) in triple-negative breast cancer patients.  Some background Triple-negative breast cancer describes cancer without the presence of the progesterone receptor, estrogen receptor and human...

Read More